NEW YORK--(BUSINESS WIRE)-- Coty Inc. (NYSE: COTY) (Paris:COTY) ("Coty" or "the Company") today announced its results for the third quarter of fiscal year 2024, ended March 31, 2024. The Company's strong above-market sales growth, reported and adjusted operating income growth, and reported and adjusted gross and operating margin expansion in Q3 solidifies nearly four years of Coty reporting results in-line to ahead of expectations. In 3Q24, Coty's net revenues grew 8% on a reported basis and 10% on a LFL basis, with reported and LFL results supported by growth in fragrances, color cosmetics,...
AMG Reports Financial and Operating Results for the First Quarter of 2024 Company reports EPS of $4.14, Economic EPS of $5.37 in first quarter Net Income (controlling interest) of $150 million, Economic Net Income (controlling interest) of $187 millionEconomic Earnings per share increased 28% year-over-year, reflecting strong business momentum and the positive impact of our capital allocation strategyIssued $450 million of 40-year junior hybrid debt and repurchased approximately $150 million in common stock WEST PALM BEACH, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AMG, a leading partner t...
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection until December 2040, and may qualify for additional U.S. patent term extension (PTE) beyond 2040Expressly provides IP protection for levosimendan at all therapeutic doses for use in PH-HFpEF Expressly provides IP protection for levosi...
AMG to Announce First-Quarter Results on May 6, 2024 Conference Call Scheduled for 8:30 a.m. Eastern Time WEST PALM BEACH, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AMG (NYSE: AMG) will report financial and operating results for the first quarter ended March 31, 2024 on Monday, May 6, 2024. A conference call will be held at 8:30 a.m. Eastern time on the same day. In addition to quarterly results, the conference call may include discussion of management’s expectations of future financial and operating results. Jay C. Horgen, President and Chief Executive Officer, Thomas M. Wojcik, Chief ...
IGM Biosciences Announces Refocusing of Sanofi Collaboration Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseases MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflamm...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 12:00 p.m. EDT. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s web...
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease Experts will explain pathophysiology of PH-HFpEF, and mechanistic rationale for levosimendan Update on the ongoing Phase 3 ...
NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain oth...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.